- $1.68bn
- $1.43bn
- $655.35m
Novocure Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Novocure Q3 Revenue USD 127.321 Million Vs. IBES Estimate USD 128.8 Million
Novocure Ltd expected to post a loss of 52 cents a share - Earnings Preview
Entered Agreement With Stanford University To Establish Stanford School Of Medicine Tumor Treating Fields Research Program
U.S. STOCKS ON THE MOVE-Danaher, Goldman Sachs, Generac Holdings
U.S. STOCKS ON THE MOVE-3M, RPT Realty, CN Energy
Novocure plunges as electric-signal therapy fails ovarian cancer study
Novocure's cancer therapy fails to meet main goal in late-stage trial (updated)
Novocure says its ovarian cancer therapy did not meet main goal in late-stage trial
Brief: Novocure Provides Update On Phase 3 Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy In Platinum-Resistant Ovarian Cancer
Novocure Ltd reports results for the quarter ended in June - Earnings Summary
Brief: Novocure Q2 Revenue USD 126.051 Million Vs. IBES Estimate USD 124.3 Million
Novocure Ltd expected to post a loss of 50 cents a share - Earnings Preview
Brief: Novocure Announces Favorable Independent Data Monitoring Committee Recommendation To Continue Phase 3 PANOVA-3 Clinical Trial
Zai Lab down as lung cancer device study raises concerns over commercial use
U.S. STOCKS ON THE MOVE-Cenovus Energy, Compass Pathways,
NovoCure falls as analysts raise concerns over data for lung cancer therapy
U.S. STOCKS ON THE MOVE-NovoCure, Intuit, Splash Beverage
NovoCure falls as analysts raise concerns over data for lung cancer therapy